5.2 RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs

ACSM Certified Clinical Exercise Physiologist ACSM-CEP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The ACSM-CEP Role, Job Definition & Scope of Practice 1.2 Exam Format, Domain Weights & Scoring 1.3 Eligibility, Study Planning & Test-Day Strategy

2 Applied Exercise Physiology & Metabolic Calculations

Bioenergetics & Energy Systems (ATP-PC, glycolytic, oxidative) Acute Cardiorespiratory & Metabolic Responses to Aerobic Exercise Responses to Resistance Exercise & Chronic Training Adaptations ACSM Metabolic Equations, METs & Interpreting VO₂ / RER / Ventilatory Threshold

3 Pathophysiology of Clinical Populations

3.1 Coronary Artery Disease, Myocardial Infarction & Revascularization (PCI/CABG) 3.2 Heart Failure, Valvular Disease & Cardiac Rhythm Disorders 3.3 Hypertension, Dyslipidemia & Peripheral Artery Disease 3.4 Pulmonary Disease: COPD, Asthma & Restrictive/Interstitial Disorders 3.5 Diabetes, Metabolic Syndrome & Obesity 3.6 Renal Disease & Musculoskeletal/Orthopedic Conditions 3.7 Neuromuscular, Neurological & Cognitive Conditions (stroke, MS, Parkinson's, SCI) 3.8 Neoplastic, Immunologic & Hematologic Disorders (cancer, HIV/AIDS, anemia)

4 Clinical ECG Interpretation

4.1 ECG Leads, Waveforms, Rate & Rhythm Determination 4.2 Arrhythmias & Conduction Blocks 4.3 Ischemia, Injury & Infarction (ST changes, exercise-induced) 4.4 Drug & Electrolyte ECG Effects; Resting/Exercise Monitoring Setup & Lead Placement

5 Pharmacology for the Clinical Exercise Physiologist

5.1 Beta-Blockers, Calcium-Channel Blockers & Nitrates 5.2 RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs 5.3 Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents 5.4 Medication Effects on HR/BP & Exercise Response; Dose/Meal/Dialysis Timing

6 Patient Assessment (Domain I, 18%)

6.1 Medical Records, HIPAA/HITRUST, Charting & Physician Referral 6.2 Patient Interview, Medical History & Medication Reconciliation 6.3 Resting Vital Signs, Body Composition & Resting ECG 6.4 Preparticipation Health Screening & Level of Monitoring (PAR-Q+, ACSM algorithm, ACC/AHA · GOLD · ADA · AACVPR) 6.5 Assessing Patient Goals, Readiness & Psychosocial Status

7 Clinical Exercise Testing (Domain II, 18%)

Submaximal Aerobic Tests (treadmill, cycle, step, 6-minute walk) Musculoskeletal Fitness, Mobility & Balance Testing Maximal Symptom-Limited GXT: Protocols, Contraindications & ECG Prep Test Termination: Relative & Absolute Indications Interpreting & Reporting Results (ECG response, RPP, claudication, Duke Treadmill Score, VO₂/RER/AT)

8 Exercise Prescription for Clinical Populations (Domain III, 22%)

FITT-VP Principles, Progression & Prescription Foundations Ex Rx for Cardiovascular Disease (CAD, HF, HTN, PAD, post-revascularization) Ex Rx for Pulmonary Disease (COPD, asthma; breathing techniques, supplemental O2) Ex Rx for Diabetes, Metabolic Syndrome & Obesity Ex Rx for Musculoskeletal, Neuromuscular, Neoplastic & Other Conditions Communicating Intensity (THR, RPE, talk test), Monitoring & Modifying the Prescription

9 Exercise Training & Leadership (Domain IV, 24%)

9.1 Discussing the Training Plan, Clinician & Patient Expectations/Goals 9.2 Instructing & Modifying Exercise Modes (cardiorespiratory, strength/endurance, flexibility, coordination, agility) 9.3 Patient Monitoring & Supervision During Exercise (telemetry, oximetry, glucometry, ECG) 9.4 Contraindications to Training & Modifying Recommendations 9.5 Documenting Clinical Status, Reporting Adverse Events & Interdisciplinary Coordination

10 Education & Behavior Change (Domain V, 13%)

10.1 Behavioral-Health Screening & Recognizing Distress (PHQ-9, Beck, SF-36; referral) 10.2 Patient Education, Health Literacy & Disease Self-Management 10.3 Motivational Interviewing & Behavior-Change Theories (Transtheoretical, HBM, Social Cognitive, Five-A's) 10.4 Promoting Adherence, Self-Efficacy, Relapse Prevention & Social Support

11 Legal, Professional & Emergency Management (Domain VI, 5%)

11.1 Emergency Equipment, Crash Cart Inspection & Emergency Procedures 11.2 CPR/AED/BLS/ACLS, Universal Precautions & EMS Activation 11.3 Scope of Practice, Legal/Ethical Standards, Liability/Negligence, Informed Consent & Professional Organizations (ACSM/AACVPR/AHA)

5.2 RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs

Key Takeaways Explain This Topic AI

ACE inhibitors and ARBs lower blood pressure with minimal direct effect on the exercise heart-rate response, but raise the risk of exercise or post-exercise hypotension.

Diuretics carry a hypokalemia-driven arrhythmia risk that is highest during the post-exercise recovery period, when serum potassium continues to fall.

Amiodarone's pulmonary and thyroid toxicity can present as an unexplained decline in exercise tolerance rather than an obvious drug reaction.

Statins carry no direct hemodynamic effect but can cause myalgia or, rarely, rhabdomyolysis; new muscle pain after starting or increasing a statin dose should be reported.

Antiplatelets and anticoagulants have no direct effect on the exercise response itself but require avoiding contact and high-fall-risk activities due to bleeding risk.

Last updated: July 2026

RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs

Quick Answer: ACE inhibitors, ARBs, and diuretics primarily affect blood pressure with little direct effect on the exercise heart-rate response, but diuretics carry an important arrhythmia risk from electrolyte loss — highest in the post-exercise recovery window. Statins mainly threaten muscle tissue, not hemodynamics, and antiplatelets/anticoagulants mainly threaten bleeding safety, not the exercise response itself.

RAAS Agents: ACE Inhibitors & ARBs

ACE inhibitors ("-pril": lisinopril, enalapril, ramipril) block the conversion of angiotensin I to angiotensin II; angiotensin receptor blockers (ARBs) ("-sartan": losartan, valsartan) block the angiotensin II receptor directly. Both lower resting and exercise blood pressure through reduced vasoconstriction, with little to no direct effect on the heart-rate response to exercise — unlike beta-blockers, standard heart-rate-based intensity prescriptions remain valid for patients on these agents alone.

The main exercise-safety concern is exercise-associated or post-exercise hypotension , particularly early in a program or shortly after a dose increase — monitor blood pressure through the cool-down and caution patients about rapid postural changes. A useful chart-review distinguisher: ACE inhibitors cause a dry, nonproductive cough in a meaningful minority of patients (bradykinin-mediated); ARBs largely avoid this side effect. Don't mistake this cough for exercise-induced bronchospasm or a cardiac symptom during the patient interview. Aldosterone antagonists (spironolactone, eplerenone), often paired with these agents in heart failure, are potassium-sparing and raise hyperkalemia risk, especially with renal impairment.

Diuretics

Thiazides (hydrochlorothiazide, chlorthalidone), loop diuretics (furosemide, bumetanide), and potassium-sparing agents (spironolactone) reduce blood volume to lower blood pressure or manage fluid overload in heart failure. The central patient-safety concern is electrolyte depletion — especially hypokalemia and hypomagnesemia — which raises the risk of cardiac arrhythmia . This risk is not evenly distributed across a session: it is highest during the post-exercise recovery period , when serum potassium continues to decline after exercise-induced shifts, making unexplained palpitations or ectopy in recovery worth taking seriously in a diuretic-treated patient.

Diuretics also raise the risk of dehydration, hypovolemia, exercise-induced or orthostatic hypotension, and heat illness in warm environments. They have little direct effect on resting heart rate, but volume depletion can produce an exaggerated heart-rate response for a given workload. Encourage adequate hydration, and treat new cramps, palpitations, or dizziness as possible signs of an electrolyte imbalance worth reporting rather than routine fatigue.

Antiarrhythmics

This is a broad drug class (Vaughan-Williams classes I–IV), but amiodarone is the agent most CEPs will encounter, used for atrial fibrillation and ventricular arrhythmias. Amiodarone's long half-life and iodine content bring a distinct toxicity profile: pulmonary toxicity (roughly 10% of patients, more likely at higher cumulative doses and longer treatment duration — watch for new dyspnea, dry cough, or an unexplained drop in exercise tolerance) and thyroid dysfunction (either hypo- or hyperthyroid, requiring periodic TSH/T4 monitoring), along with photosensitivity and corneal deposits. A CEP who notices a gradual, otherwise-unexplained decline in a patient's functional capacity on amiodarone should consider — and report — a possible toxicity effect rather than assume simple deconditioning.

Lipid-Lowering: Statins

Statins (atorvastatin, simvastatin, rosuvastatin) have no direct effect on heart rate or blood pressure . Their exercise-relevant risk is muscular: statin-associated muscle symptoms (myalgia, weakness) affect a meaningful minority of patients, and rare but serious rhabdomyolysis (severe muscle breakdown with dark urine and marked CK elevation) can occur. New, unexplained, often bilateral muscle pain or weakness in a patient who recently started or increased a statin dose should be reported rather than dismissed as ordinary training soreness.

Antithrombotics: Antiplatelets & Anticoagulants

Antiplatelets (aspirin, clopidogrel, ticagrelor) and anticoagulants (warfarin, DOACs such as apixaban and rivaroxaban, heparin) have no direct hemodynamic effect on the exercise response. Their safety concern is increased bleeding and bruising risk — the exercise prescription should avoid contact/collision activities and high-fall-risk modes, with extra caution for balance-impaired patients (e.g., post-stroke) on anticoagulation. Watch for unusual bruising, hematuria, or dark stools as signs warranting physician follow-up.

Digoxin: A Special Case

Digoxin is used to control ventricular rate in atrial fibrillation and to manage symptoms in some heart failure patients. Two exam-relevant facts stand out. First, digoxin classically produces a "scooped" or coving ST-segment depression on the resting and exercise ECG that can mimic true ischemia — this is covered in detail later in this chapter, but it means an ST-segment change in a digoxin patient cannot automatically be read as a positive ischemia finding. Second, digoxin has a narrow therapeutic window , and toxicity risk rises sharply in the presence of hypokalemia — exactly the electrolyte disturbance a concurrent thiazide or loop diuretic can cause. Watch for classic toxicity signs (nausea, visual disturbances such as yellow-green halos, and new arrhythmias) in any patient on both a diuretic and digoxin, and treat this drug combination as one that warrants extra attention to electrolyte status.

Drug Class vs. Exercise Safety Concern

Drug Class HR/BP Effect Primary Exercise Safety Concern CEP Monitoring Action

ACE-I / ARB Decreased BP; minimal HR effect Exercise/post-exercise hypotension Monitor BP through cool-down; note dry cough (ACE-I only)

Diuretics Minimal resting HR effect; decreased BP Hypokalemia-driven arrhythmia (highest post-exercise); dehydration Hydration reminders; treat cramps/palpitations as possible electrolyte signs

Amiodarone Variable Pulmonary/thyroid toxicity masquerading as fatigue Track unexplained functional decline as a toxicity flag

• Statins None Myalgia/rhabdomyolysis Distinguish new muscle pain from training soreness
• Antiplatelets/Anticoagulants None Bleeding/bruising Avoid contact and high-fall-risk activities

Digoxin Slows ventricular rate False-positive ST depression; toxicity risk with hypokalemia Don't over-read ST changes; watch for toxicity signs if also on a diuretic